Business Context and Reporting Period
This Form 8-K was filed by Actinium Pharmaceuticals, Inc. (ATNM) on June 18, 2026. The report addresses a compliance issue with the NYSE American LLC regarding continued listing standards.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. However, it notes that the company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years, triggering the listing standard review.
Material Changes
The material event reported is the submission of a compliance plan to the NYSE American. This action follows a notice received on May 27, 2026, stating the company failed to meet Section 1003(a)(ii) of the NYSE American Company Guide, which requires listed companies with recent losses to maintain stockholders' equity of at least $4.0 million.
Guidance, Outlook, and Risks
Management intends to take actions outlined in the submitted compliance plan to restore compliance with listing standards. The primary risk identified is the potential loss of listing status on the NYSE American if the company fails to meet the stockholders' equity requirement or successfully implement its compliance plan.
Investor Verification Checklist
- Verify the current stockholders' equity balance to confirm if it remains below the $4.0 million threshold.
- Review the specific actions detailed in the compliance plan submitted to the NYSE American.
- Monitor subsequent filings for updates on the exchange's decision regarding the compliance plan.
- Check the company's most recent financial statements to confirm the extent of losses in the last four fiscal years.